The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 3, 2015, Pages 369-379

  Dubovsky, Steven L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

CYP P450; Depression; Genetic; Metabolism; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; SEROTONIN UPTAKE INHIBITOR;

AEROBIC METABOLISM; DEPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; PHARMACOGENOMICS; REVIEW; TREATMENT RESPONSE; GENETICS; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS; PROCEDURES;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84923042613     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.998996     Document Type: Review

References (46)

1. Trembplay J, Hamet P. Role of genomics on the path to personalized medicine. Metabolism 2013;62:S2-5
2. Malhotra AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17(8):760-9
3. Hamilton SP. The promise of psychiatric pharmacogenomics. Biol Psychiatry 2014;77(1):29-35
4. Crettol S, de Leon J, Hiemke C, et al. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014;95(3):254-7
5. Singh AB, Bousman CA, Ng C, et al. Antidepressant pharmacogenetics. Curr Opin Psychiatry 2014;27(1):43-51.
6. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry 2014;59(2):62-75
7. Lombard J, Doraiswamy PM. What is the role of pharmacogenetics in clinical psychiatry? Expert Opin Drug Metab Toxicol 2013;9(1):1-4
8. Preissner SC, Hoffmann MF, Preissner R, et al. Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 2013;8(12):e82562
9. Jones DS, Perlis RH. Pharmacogenetics, race, and psychiatry: prospects and challenges. Harv Rev Psychiatry 2006;14(2):92-108.
10. Wladyslawa AD. The influence of longterm treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol 2005;1(2):203-17
11. Zanger UM, Klein K, Thomas M, et al. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin Pharmacol Ther 2014;95(3):258-61.
12. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9(5):442-73
13. Seden K, Dickinson L, Khoo S, et al. Grapefruit-drug interactions. Drugs 2010;70(18):2373-407
14. Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392(6):1093-108
15. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104(3):173-92
16. Kitzmiller JP, Groen DK, Phelps MA, et al. Pharmacogenomic testing: relevance in medical practice. Cleve Clin J Med 2011;78(4):243-57
17. Misaka S, Kawabe K, Onoue S, et al. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes. Drug Metab Pharmacokinet 2013;28(3):244-9.
18. Yamasaki I, Yamada M, Uotsu N, et al. Inhibitory effects of kale ingestion on metabolism by cythochrome P450 enzymes. Biomed Res 2012;33(4):235-42
19. Pirmohamed M. Drug-grapefruit juice interactions. two mechanisms are clear but individual respponses vary. BMJ 2013;346:f1.
20. Nadkarni A, Oldham MA, Howard M, et al. Psychotropics: updated review of the literature. Pharmacotherapy 2012;32(10):932-42
21. Alter CN, Hornberger J, Shewade A, et al. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry 2013;25(5):509-33
22. de Leon J, Arranz GR. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008;28(4):599-617
23. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014;95(4):376-82
24. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR∗D sample. PLoS One 2008;3(4):e1872.
25. Preskorn SH. Complexities of personalized medicine: how genes, drugdrug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect. J Psychiatric Practice 2013;19:397-405
26. Preskorn SH, Kane CP, Lobello K, et al. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 2013;74(6):614-21.
27. Catherine M, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693
28. Lanni C, Racchi M, Govoni S. Do we need pharmacogenetics to personalize antidepressant therapy? Cell Mol Life Sci 2013;70(18):3327-40
29. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012;22(4):239-58
30. Rosenhagen MC, Uhr M. The clinical impact of ABCB1 polymorphisms in the treatment of psychiatric diseases. Curr Pharm Des 2011;17(26):2843-51.
31. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr 2014;19(2):165-75
32. Xu Q, Wu X, Xiong Y, et al. Pharmacogenomics can improve antipsychotic treatment in schizophrenia. Front Med 2013;7(2):180-90
33. Keers R, Aitchison KJ. Pharmacokinetics of antidepressant response. Expert Rev Neurother 2011;11(1):101-25
34. Costa e Silva JA. Personalized medicine in psychiatry: new technologies and approaches. Metabolism 2013;62:S40-4
35. Hall-Flavin DK, Winner JG, Allen J, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2012;2:e172
36. Hall-Flavin DK, Winner JG, Allen J, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 2013;23(10):535-48
37. Winner JG, Carhart JM, Alter CN, et al. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 2013;16(89):219-27
38. Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem 2014;60(1):53-9.
39. Chung WH, Hung SI, Hong HS, et al. Medical genetics. a marker for stevensjohnson syndrome. Nature 2004;428(6982):486
40. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic efffects and HLA-B∗1502 screening in Taiwan. N Engl J Med 2011;364(12):1126-33
41. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-D1B1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72(4):458-63
42. Perera V, Gross AS, Polasek TM, et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol 2013;9(9):1115-37
43. Seeringer A, Kirchheiner J. Pharmacogeneticcs-guided dose modifications of antidepressants. Clin Lab Med 2008;28(4):619-26
44. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55(12):1128-32
45. Domschke K. Clinical and molecular genetics of psychotic depression. Schizophr Bull 2013;39(4):766-75
46. Wall CA, Croarkin PE, Swintak C, et al. Psychiatric pharmacogenomics in pediatric psychopharmacology. Child Adolesc Psychiatr Clin N Am 2013;21(4):773-88